First Regulatory Qualification of a Novel Digital Endpoint in Duchenne Muscular Dystrophy: A Multi-Stakeholder Perspective on the Impact for Patients and for Drug Development in Neuromuscular Diseases. (2021)
Attributed to:
Oxford P2D: From Technologies to Therapies
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1159/000517411
PubMed Identifier: 34723071
Publication URI: http://europepmc.org/abstract/MED/34723071
Type: Journal Article/Review
Volume: 5
Parent Publication: Digital biomarkers
Issue: 2
ISSN: 2504-110X